Skip to main content

Part of UT Health San Antonio

Cancer Center - UT Health San AntonioCancer Center - UT Health San Antonio

Part of UT Health San Antonio

Search

Patient Links

Give

Contact Us | 210-450-1000 800-340-2872

A Cancer Center designated by the National Cancer Institute

Patient Information

  • My Chart
  • Pay Bill Online
  • Open Clinical Trials
  • Medical Records Request
  • Insurance We Accept
  • Patient Rights & Responsibilities
  • Map / Directions / Parking
  • Living Well Newsletter

Forms

  • New Patient Information Sheet
  • Authorization for Cancer Center to Request Your Patient Health Records
  • Signature Form

 Close Quicklinks

Menu
  • Home
  • Cancer Types
  • Clinical Trials
  • Our Doctors
  • Wellness/Support
  • Research/Academics
  • Make an Appointment

You are here

  • Clinical Trials
  • Open Clinical Trials
  • A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis (CTMS# 17-0117)

A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis (CTMS# 17-0117)

The primary objective of the study is:
To evaluate the effect of the addition of navitoclax to ruxolitinib on spleen volume

The secondary objectives of the study are:
To assess the effect of the addition of navitoclax to ruxolitinib on total symptom score (TSS) as assessed by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0 diary
To evaluate the effect of the addition of navitoclax to ruxolitinib on bone marrow fibrosis
To determine the overall response rate (ORR = sum of rates of complete remission [CR] +
partial remission [PR]) associated with the addition of navitoclax to ruxolitinib
To determine the rate of anemia response associated with the addition of navitoclax to
ruxolitinib
To describe the safety profile and PK profile observed with the addition of navitoclax to
ruxolitinib

Principal Investigator

Ruben Mesa

Type of Cancer Treated

  • Other Hematopoietic

Get study information at ClinicalTrials.gov

More information on this study

Map image of UT Health location

UT Health San Antonio M.D. Anderson Cancer Center

7979 Wurzbach Road
San Antonio, TX 78229

210-450-1000

Stay connected

  • Facebook
  • Twitter
  • YouTube
  • About Us
  • Contact Us
  • For Researchers
  • Job Opportunities
  • Maps & Directions
  • Patient Rights and Responsibilities
  • Language Assistance
We make lives better ®

We're a part of UT Health San Antonio, provider of comprehensive health,  dental   and  cancer care,  advanced academics  and  life-saving research.

 
NCI Cancer Center. A Cancer Center Designated by the National Cancer Institute.

Web Privacy | Links from websites affiliated with UT Health's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.